These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 23621211)

  • 21. Cancer-Associated Fibroblasts Accelerate Malignant Progression of Non-Small Cell Lung Cancer via Connexin 43-Formed Unidirectional Gap Junctional Intercellular Communication.
    Luo M; Luo Y; Mao N; Huang G; Teng C; Wang H; Wu J; Liao X; Yang J
    Cell Physiol Biochem; 2018; 51(1):315-336. PubMed ID: 30453281
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epithelial-Mesenchymal Transition in Non Small-cell Lung Cancer.
    Tsoukalas N; Aravantinou-Fatorou E; Tolia M; Giaginis C; Galanopoulos M; Kiakou M; Kostakis ID; Dana E; Vamvakaris I; Korogiannos A; Tsiambas E; Salemis N; Kyrgias G; Karameris A; Theocharis S
    Anticancer Res; 2017 Apr; 37(4):1773-1778. PubMed ID: 28373440
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinicopathological significance of lymphatic vessel density marked by D2-40 and E-cadherin expression in non-small-cell lung cancer.
    Jin S; Zhu W; Shi Q; Zhang Z; Guo R
    Med Oncol; 2012 Dec; 29(5):3157-61. PubMed ID: 22528515
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TIMM50 promotes tumor progression via ERK signaling and predicts poor prognosis of non-small cell lung cancer patients.
    Zhang X; Han S; Zhou H; Cai L; Li J; Liu N; Liu Y; Wang L; Fan C; Li A; Miao Y
    Mol Carcinog; 2019 May; 58(5):767-776. PubMed ID: 30604908
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical outcomes of downregulation of E-cadherin gene expression in non-small cell lung cancer.
    Zheng SY; Hou JY; Zhao J; Jiang D; Ge JF; Chen S
    Asian Pac J Cancer Prev; 2012; 13(4):1557-61. PubMed ID: 22799366
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Retinoic acid-related orphan receptor C isoform 2 expression and its prognostic significance for non-small cell lung cancer.
    Huang Q; Fan J; Qian X; Lv Z; Zhang X; Han J; Wu F; Chen C; Du J; Guo M; Hu G; Jin Y
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):263-72. PubMed ID: 26319393
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Defected expression of E-cadherin in non-small cell lung cancer.
    Fei Q; Zhang H; Chen X; Wang JC; Zhang R; Xu W; Zhang Z; Zou W; Zhang K; Qi Q; Wang M; Tao S; Luo Z
    Lung Cancer; 2002 Aug; 37(2):147-52. PubMed ID: 12140137
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent.
    Gouyer V; Conti M; Devos P; Zerimech F; Copin MC; Créme E; Wurtz A; Porte H; Huet G
    Cancer; 2005 Apr; 103(8):1676-84. PubMed ID: 15754326
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression and significance of Cx43 and E-cadherin in gastric cancer and metastatic lymph nodes.
    Tang B; Peng ZH; Yu PW; Yu G; Qian F
    Med Oncol; 2011 Jun; 28(2):502-8. PubMed ID: 20373058
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interferon regulatory factor 4 (IRF4) is overexpressed in human non‑small cell lung cancer (NSCLC) and activates the Notch signaling pathway.
    Qian Y; Du Z; Xing Y; Zhou T; Chen T; Shi M
    Mol Med Rep; 2017 Nov; 16(5):6034-6040. PubMed ID: 28849037
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased expression of SOX4 is a biomarker for malignant status and poor prognosis in patients with non-small cell lung cancer.
    Wang D; Hao T; Pan Y; Qian X; Zhou D
    Mol Cell Biochem; 2015 Apr; 402(1-2):75-82. PubMed ID: 25567207
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MDK Protein Overexpression Correlates with the Malignant Status and Prognosis of Non-small Cell Lung Cancer.
    Yuan K; Chen Z; Li W; Gao CE; Li G; Guo G; Yang Y; Ai Y; Wu L; Zhang M
    Arch Med Res; 2015 Nov; 46(8):635-41. PubMed ID: 26656665
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Expressions of E-cadherin in non-small cell lung cancer and it correlation with prognosis].
    Qiao GB; Wu YL; Ou W; Yang XN; Zhong WZ; Lin JY; Zhao J; Xie D; Guan XY
    Zhonghua Wai Ke Za Zhi; 2005 Jul; 43(14):913-7. PubMed ID: 16083620
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Decrease of PDSS2 expression, a novel tumor suppressor, in non-small cell lung cancer.
    Chen P; Yu J; Knecht J; Chen Q
    Cancer Epidemiol; 2013 Apr; 37(2):166-71. PubMed ID: 23312889
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Frequent down-regulation of pim-1 mRNA expression in non-small cell lung cancer is associated with lymph node metastases.
    Warnecke-Eberz U; Bollschweiler E; Drebber U; Pohl A; Baldus SE; Hoelscher AH; Metzger R
    Oncol Rep; 2008 Sep; 20(3):619-24. PubMed ID: 18695914
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased BCAR1 predicts poor outcomes of non-small cell lung cancer in multiple-center patients.
    Deng B; Sun Z; Jason W; Yang P
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3(0 3):S701-8. PubMed ID: 23904007
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Downregulated vimentin and upregulated E-cadherin in T1 stage non-small-cell lung cancer: does it suggest a mesenchymal-epithelial transition?
    Luo T; Wang L; Wu P; Gong W; Chen W; Zhao H; Zheng Z
    Neoplasma; 2017; 64(5):693-699. PubMed ID: 28592120
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The value of E-cadherin/beta-catenin expression in imprints of NCSLC: relationship with clinicopathological factors.
    Pagaki E; Patsouris E; Gonidi M; Athanassiadou AM; Maurikakis M; Athanassiades P; Chelidonis G; Athanassiadou P
    Diagn Cytopathol; 2010 Jun; 38(6):419-24. PubMed ID: 20474081
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overexpression of Ang-2 mRNA in non-small cell lung cancer: association with angiogenesis and poor prognosis.
    Takanami I
    Oncol Rep; 2004 Oct; 12(4):849-53. PubMed ID: 15375511
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of E-cadherin in lung carcinoma, other than those with small cells (NSCLC).
    Grigoraş ML; Arghirescu TS; Folescu R; Talpoş IC; Gîndac CM; Zamfir CL; Cornianu M; Anghel MD; Levai CM
    Rom J Morphol Embryol; 2017; 58(4):1317-1325. PubMed ID: 29556623
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.